Selecta Biosciences (NASDAQ: SELB) is one of 287 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Selecta Biosciences to related businesses based on the strength of its valuation, institutional ownership, risk, analyst recommendations, profitability, dividends and earnings.
Insider & Institutional Ownership
54.4% of Selecta Biosciences shares are owned by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 41.9% of Selecta Biosciences shares are owned by insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a summary of current ratings and recommmendations for Selecta Biosciences and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Selecta Biosciences Competitors||925||3351||11863||238||2.70|
Selecta Biosciences presently has a consensus target price of $29.00, indicating a potential upside of 162.92%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.65%. Given Selecta Biosciences’ stronger consensus rating and higher possible upside, research analysts plainly believe Selecta Biosciences is more favorable than its rivals.
This table compares Selecta Biosciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Selecta Biosciences Competitors||-5,441.68%||-162.70%||-35.92%|
Earnings & Valuation
This table compares Selecta Biosciences and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Selecta Biosciences||$8.08 million||-$36.21 million||-3.56|
|Selecta Biosciences Competitors||$290.27 million||$35.99 million||59.53|
Selecta Biosciences’ rivals have higher revenue and earnings than Selecta Biosciences. Selecta Biosciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Selecta Biosciences has a beta of -7.16, meaning that its share price is 816% less volatile than the S&P 500. Comparatively, Selecta Biosciences’ rivals have a beta of 1.03, meaning that their average share price is 3% more volatile than the S&P 500.
Selecta Biosciences beats its rivals on 7 of the 13 factors compared.
About Selecta Biosciences
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.